IART تصريحات هيئة الأوراق المالية والبورصات - Integra LifeSciences Holdings Corporation- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

LEI	WB7IJCYY8YFTENS4O147
CIK	917520

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Integra LifeSciences Holdings Corporation

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

July 31, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 INTEGRA LIFESCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporatio
July 31, 2025	S-8	As filed with the Securities and Exchange Commission on July 31, 2025 As filed with the Securities and Exchange Commission on July 31, 2025 Registration No.
July 31, 2025	EX-FILING FEES	Filing Fee Table.+ Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Integra LifeSciences Holdings Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.
July 31, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-26224 INTEGRA LIF
July 31, 2025	EX-99.1	Integra LifeSciences Reports Second Quarter 2025 Financial Results News Release Integra LifeSciences Reports Second Quarter 2025 Financial Results PRINCETON, N.
July 31, 2025	EX-24	Power of Attorney. + Exhibit 24.1 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mojdeh Poul, Lea Knight, and Lesha Shinn, or any one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file
June 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 INTEGRA LIFESCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporation
June 9, 2025	EX-4.1	Amendment No. 1, dated June 6, 2025, to that Seventh Amended and Restated Credit Agreement, among Integra LifeSciences Holdings Corporation, the lenders party thereto, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Citibank N.A., JPMorgan Chase Bank, N.A., Morgan Stanley MUFG Loan Partners, LLC, PNC Bank, N.A., Truist Bank and Wells Fargo Bank, N.A., as Co-Syndication Agents, and The Bank of Nova Scotia, BMO Harris Bank N.A., BNP Paribas, Capital One, National Association, Citizens Bank, N.A., DNB Bank ASA, New York Branch, Santander Bank, N.A. and TD Bank, N.A., as Co-Documentation Agents Exhibit 4.1 AMENDMENT NO. 1, dated as of June 6, 2025 (this “Amendment”) to the Seventh Amended and Restated Credit Agreement, dated as of March 24, 2023 (as amended, restated, modified and supplemented from time to time prior to the date hereof, the “Existing Credit Agreement”), by and among INTEGRA LIFESCIENCES HOLDINGS CORPORATION, a Delaware corporation (the “Borrower”), the lenders and issuin
May 30, 2025	SD	United States Securities and Exchange Commission Washington, D.C. 20549 FORM SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) United States Securities and Exchange Commission Washington, D.C. 20549 FORM SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-26224 51-0317849 (State or other jurisdiction of incorporation or organization) Commission File Number (I.R.S. Employer Identification No.) 1100 CAMPUS ROAD PRINCETON, NEW JERSEY 0
May 30, 2025	EX-1.01	Conflict Minerals Report Exhibit 1.01 Conflict Minerals Report of Integra LifeSciences Holdings Corporation Filed on May 30, 2025 As required by Items 1.01 and 1.02 of Form SD This Conflict Minerals Report (this “Report”) of Integra LifeSciences Holdings Corporation (the “Company,” “we,” “us,” and “our”) for the year ended December 31, 2024 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934,
May 13, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporation
May 13, 2025	EX-10.1	Amendment No. 2 to the Integra LifeSciences Holdings Corporatio Exhibit 10.1 AMENDMENT NO. 2 TO THE INTEGRA LIFESCIENCES HOLDINGS CORPORATION FIFTH AMENDED AND RESTATED 2003 EQUITY INCENTIVE PLAN THIS AMENDMENT (this “Amendment”) to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “Plan”), is adopted by the Board of Directors (the “Board”) of Integra LifeSciences Holdings Corporation (the “Com
May 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-26224 INTEGRA LI
May 5, 2025	EX-99.1	Integra LifeSciences Reports First Quarter 2025 Financial Results News Release Integra LifeSciences Reports First Quarter 2025 Financial Results PRINCETON, N.
May 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 INTEGRA LIFESCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporation
April 4, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
February 25, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
February 25, 2025	EX-19.1(B)	Integra LifeSciences Holdings Corporation Trading Window Group Policy (as amended February 20, 2025) IART-2024-12.31-EX-19.1(b) Distribution: Integra Trading Window Distribution Group Subject: Trading Window Group Policy Effective Date: May 17, 2005 Page Section: Revision Date: February 20, 2025 Issued by the: Law Department Note: Compliance with this Trading Window Group Policy (this “Policy”) of Integra LifeSciences Holdings Corporation (the “Company”) is required in addition to compliance with
February 25, 2025	EX-4.4	Description of Securities IART-2024.12.31-Exhibit 4.4 Description of the Company’s Common Stock Registered Under Section 12 of the Exchange Act The following is a description of the common stock of Integra LifeSciences Holdings Corporation (the “Company”). The description does not purport to be complete and is subject to and qualified in its entirety by reference to the Company’s amended and restated certificate of incorpo
February 25, 2025	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
February 25, 2025	EX-99.1	INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS News Release Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance Princeton, New Jersey, February 25, 2025 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024.
February 25, 2025	EX-21.1	Subsidiaries of the Company IART-2024.12.31-Exhibit 21.1 Subsidiaries of Integra LifeSciences Holdings Corporation Name of Subsidiary State or Country of Incorporation or Organization Acclarent, Inc. Delaware ACell, Inc. Delaware Arkis Biosciences Inc. Delaware Ascension Orthopedics Limited United Kingdom BIMECO, Inc. Florida BioD, LLC Delaware BioDlogics, LLC Delaware BioRecovery, LLC Delaware CardioDyne, Inc. Massachusetts
February 25, 2025	EX-19.1(A)	Integra LifeSciences Holdings Corporation Trading in Securities by Company Personnel Policy (as amended February 20, 2025) IART-2024-12.31-EX-19.1(a) Distribution: All Company Personnel Subject: Trading in Securities by Company Personnel Policy Effective Date: September 29, 2005 Page Section: Revision Date: February 20, 2025 Issued by the: Law Department Note: This policy is supplemented by a shorter FAQ which is also available on the Company’s internal policy portal. We encourage you to read the FAQ in conjunction wi
February 25, 2025	EX-10.11(C)	Consulting Agreement, dated November 4, 2024, by and between Integra LifeSciences Holdings Corporation, Integra LifeSciences Corporation and Jan De Witte IART-2024.12.31-Exhibit 10.11(c) CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”), dated as of November 4, 2024 to be effective as of January 6, 2025 (the “Transition Date”) is entered into by and between Integra LifeSciences Holdings Corporation (“Holdings”) and Integra LifeSciences Corporation (“OpCo” and, together with Holdings, the “Company”), and Jan De Witte (“Consultant”).
January 6, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
December 17, 2024	EX-10.1	Change in Control Severance Program Exhibit 10.1 INTEGRA LIFESCIENCES HOLDINGS CORPORATION CHANGE IN CONTROL SEVERANCE PROGRAM This Change in Control Severance Program (this “Program”) is effective as of January 1, 2025 (the “Effective Date”). This Program is designed to provide selected officers and key employees of Integra LifeSciences Holdings Corporation (the “Company”) with certain benefits upon a Qualifying Termination in conn
December 17, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
November 12, 2024	SC 13G/A	IART / Integra LifeSciences Holdings Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Integra LifeSciences Holdings Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a
November 4, 2024	EX-FILING FEES	Filing Fee Table.+ Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Integra LifeSciences Holdings Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.
November 4, 2024	S-8	As filed with the Securities and Exchange Commission on November 4, 2024 As filed with the Securities and Exchange Commission on November 4, 2024 Registration No.
November 4, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-26224 INTEGR
November 4, 2024	EX-10.1	Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Restricted Stock Unit Award Agreement Exhibit 10.1 Notice of Grant of Award and Award Agreement Integra LifeSciences Holdings Corporation ID: 51-0317849 1100 Campus Road Princeton, New Jersey 08540 [ ] [ ] [ ] Award Number: [ ] Plan: [ ] ID: [ ] Effective [ ], you have been granted [ ] Restricted Stock Units (RSUs) based on a closing price of US$[ ]. These units are restricted until the vest dates shown below, at which time you will r
November 4, 2024	EX-3.1(E)	Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant dated May 9, 2024 (Incorporated by reference to Exhibit 3.1(e) to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024). Exhibit 3.1(e) CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTEGRA LIFESCIENCES HOLDINGS CORPORATION Integra LifeSciences Holdings Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST: That the Board of Directors of the Corporation, actin
November 4, 2024	EX-99.1	Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer A proven healthcare executive with deep global expertise and a distinguished record in business strategy and execution, portfolio transformation, value Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer A proven healthcare executive with deep global expertise and a distinguished record in business strategy and execution, portfolio transformation, value-creating innovation, commercial excellence, and leadership development PRINCETON, New Jersey, Nov.
November 4, 2024	EX-10.1	Employment Agreement, dated November 4, 2024, by and between Integra LifeSciences Holdings Corporation, Integra LifeSciences Corporation and Mojdeh Poul (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 4, 2024) Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), by and between Integra LifeSciences Holdings Corporation, a Delaware Corporation (“Holdings”) and Integra LifeSciences Corporation (“OpCo” and, together with Holdings, the “Company”), and Mojdeh Poul (“Executive”) is entered into as of November 4, 2024 and shall be effective as of January 6, 2025 (the “Effective Date”)
November 4, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpora
November 4, 2024	EX-99.1	Integra LifeSciences Reports Third Quarter 2024 Financial Results News Release Integra LifeSciences Reports Third Quarter 2024 Financial Results PRINCETON, N.
November 4, 2024	EX-24.1	Power of Attorney. + Exhibit 24.1 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jan De Witte, Lea Knight, and Eric I. Schwartz, or any one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to
November 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 INTEGRA LIFESCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpora
August 12, 2024	SC 13G/A	IART / Integra LifeSciences Holdings Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Integra LifeSciences Holdings Corp Title of Class of Securities: Common Stock CUSIP Number: 457985208 Date of Event Which Requires Filing of this Statement: July 31, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule
July 29, 2024	EX-99.1	Integra LifeSciences Reports Second Quarter 2024 Financial Results News Release Integra LifeSciences Reports Second Quarter 2024 Financial Results PRINCETON, N.
July 29, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-26224 INTEGRA LIF
July 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 INTEGRA LIFESCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2024 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporatio
May 30, 2024	EX-1.01	Conflict Minerals Report Exhibit 1.01 Conflict Minerals Report of Integra LifeSciences Holdings Corporation Filed on May 30, 2024 As required by Items 1.01 and 1.02 of Form SD This Conflict Minerals Report (this “Report”) of Integra LifeSciences Holdings Corporation (the “Company,” “we,” “us,” and “our”) for the year ended December 31, 2023 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934,
May 30, 2024	SD	United States Securities and Exchange Commission Washington, D.C. 20549 FORM SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) United States Securities and Exchange Commission Washington, D.C. 20549 FORM SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-26224 51-0317849 (State or other jurisdiction of incorporation or organization) Commission File Number (I.R.S. Employer Identification No.) 1100 CAMPUS ROAD PRINCETON, NEW JERSEY 0
May 17, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporation
May 13, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporation
May 13, 2024	EX-10.1	Amendment No. 1 to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Exhibit 10.1 AMENDMENT NO. 1 TO THE INTEGRA LIFESCIENCES HOLDINGS CORPORATION FIFTH AMENDED AND RESTATED 2003 EQUITY INCENTIVE PLAN THIS AMENDMENT (this “Amendment”) to the Integra Lifesciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (the “Plan”) is adopted by the Board of Directors (the “Board”) of Integra LifeSciences Holdings Corporation (the “Company”) on Mar
May 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 INTEGRA LIFESCIENCES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporation
May 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-26224 INTEGRA LI
May 6, 2024	EX-99.1	Integra LifeSciences Reports First Quarter 2024 Financial Results News Release Integra LifeSciences Reports First Quarter 2024 Financial Results PRINCETON, N.
May 6, 2024	EX-10.2	Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Non-Qualified Stock Option Award Agreement – CEO Exhibit 10.2 INTEGRA LIFESCIENCES HOLDINGS CORPORATION 2003 EQUITY INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AGREEMENT NON-QUALIFIED STOCK OPTION AGREEMENT (together with the attached Notice of Grant of Stock Options and Option Agreement (“Notice of Grant”), the “Option Agreement”) made as of the date (the “Grant Date”) set forth in Notice of Grant, between Integra LifeSciences Holdings Corporatio
April 4, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
March 25, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
February 28, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
February 28, 2024	EX-10.1	Letter Agreement, dated February 27, 2024 (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 28, 2024) Exhibit 10.1 [COMPANY LETTERHEAD] February 27, 2024 Re: CEO Transition Dear Jan: This letter (this “Letter”) memorializes the understanding between you and the Company (as defined below) regarding your anticipated transition from serving as the Company’s President and Chief Executive Officer, to serving as a consultant of, and your ultimate separation from, the Company. Reference is made to that c
February 28, 2024	EX-99.1	INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS News Release Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance Princeton, New Jersey, February 28, 2024 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023.
February 28, 2024	EX-10.12F	Amendment No. 5 to Receivables Financing Agreement and Reaffirmation of Performance Guaranty, dated as of December 15, 2023, by and among, Integra Receivables LLC, Integra LifeSciences Sales LLC, as Servicer, PNC Bank, National Associations, as Administrative Agent, PNC Capital Markets LLC, as Structuring Agent, Committed Lender and Group Agent, The Bank of Nova Scotia, as Committed Lender and Group Agent, and certain lenders and group agents that are parties thereto from time to time Exhibit 10.12(f) AMENDMENT NO. 5 TO RECEIVABLES FINANCING AGREEMENT AND REAFFIRMATION OF PERFORMANCE GUARANTY This AMENDMENT NO. 5 TO RECEIVABLES FINANCING AGREEMENT AND REAFFIRMATION OF PERFORMANCE GUARANTY (this “Amendment”), dated as of December 15, 2023, is entered into by and among INTEGRA RECEIVABLES LLC (“Integra”), as borrower under the Receivables Financing Agreement (as defined below) (i
February 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
February 28, 2024	EX-4.4	Description of Securities Exhibit 4.4 Description of the Company’s Common Stock Registered Under Section 12 of the Exchange Act The following is a description of the common stock of Integra LifeSciences Holdings Corporation (the “Company”). The description does not purport to be complete and is subject to and qualified in its entirety by reference to the Company’s amended and restated certificate of incorporation, or the c
February 28, 2024	EX-99.1	Integra LifeSciences Announces Leadership Transition Plan Jan De Witte to retire as CEO by the end of 2024 Stuart Essig appointed executive chairman of the Board PRINCETON, N.J., February 28, 2024 – Integra LifeSciences Holdings Corporation (“Integra exhibit991pressreleasex Integra LifeSciences Announces Leadership Transition Plan Jan De Witte to retire as CEO by the end of 2024 Stuart Essig appointed executive chairman of the Board PRINCETON, N.
February 28, 2024	EX-2.1C	Stock Purchase Agreement, dated December 12, 2023, among Ethicon, Inc., Integra LifeSciences Holdings Corporation and Integra LifeSciences Israel Ltd. Exhibit 2.1(c) EXECUTION VERSION DC: 8759242v37 STOCK PURCHASE AGREEMENT among ETHICON, INC., INTEGRA LIFESCIENCES HOLDINGS CORPORATION and INTEGRA LIFESCIENCES ISRAEL LTD. Dated as of December 12, 2023 TABLE OF CONTENTS Page Article I Definitions and Interpretations ........................................................................................ 1 Section 1.01. Definitions. ..............
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 INTEGRA LIFESCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
February 28, 2024	EX-97.1	Integra LifeSciences Holdings Corporation Incentive Compensation Recovery Policy Exhibit 97.1 Integra LifeSciences Holdings Corporation Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Integra LifeSciences Holdings Corporation (the “Company”) on October 11, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and a
February 28, 2024	EX-21.1	Subsidiaries of the Company Exhibit 21.1 Subsidiaries of Integra LifeSciences Holdings Corporation Name of Subsidiary State or Country of Incorporation or Organization ACell, Inc. Delaware Arkis Biosciences Inc. Delaware Ascension Orthopedics Limited United Kingdom BIMECO, Inc. Florida BioD, LLC Delaware BioDlogics, LLC Delaware BioRecovery, LLC Delaware CardioDyne, Inc. Massachusetts Cathtec Incorporated Massachusetts Cavea
February 27, 2024	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Juri
February 13, 2024	SC 13G/A	IART / Integra LifeSciences Holdings Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Integra LifeSciences Holdings Corp Title of Class of Securities: Common Stock CUSIP Number: 457985208 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Sched
February 9, 2024	SC 13G	IART / Integra LifeSciences Holdings Corporation / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Integra LifeSciences Holdings Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp
February 9, 2024	SC 13G/A	IART / Integra LifeSciences Holdings Corporation / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check
December 20, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
December 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 INTEGRA LIFESCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
December 13, 2023	EX-99.1	1 Privileged and Confidential Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent® • The acquisition will become part of Integra’s Codman Specialty Surgical (CSS) division. The ear, nose and throat (ENT) category is a key area of pressreleaseprojecthawk 1 Privileged and Confidential Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent® • The acquisition will become part of Integra’s Codman Specialty Surgical (CSS) division.
December 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 INTEGRA LIFESCI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
December 13, 2023	EX-99.2	ACQUISTION OF ACCLARENT, A LEADER IN ENT SURGICAL INTERVENTIONS DECEMBER 13, 2023 Exhibit 99.2 Legal Information 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigatio acclarentacquisitioninve ACQUISTION OF ACCLARENT, A LEADER IN ENT SURGICAL INTERVENTIONS DECEMBER 13, 2023 Exhibit 99.
December 13, 2023	EX-10.1	Change in Control Severance Program changeinctrlseverancepro Exhibit 10.1 SC1:4719683.2 INTEGRA LIFESCIENCES HOLDINGS CORPORATION CHANGE IN CONTROL SEVERANCE PROGRAM This Change in Control Severance Program (this “Program”) is effective as of January 1, 2024 (the “Effective Date”). This Program is designed to provide selected officers and key employees of Integra LifeSciences Holdings Corporation (the “Company”) with certain benefit
December 13, 2023	EX-99.1	Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors Princeton, New Jersey, December 12, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announce pressreleasejeffgraves Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors Princeton, New Jersey, December 12, 2023 (GLOBE NEWSWIRE) - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company’s board
October 25, 2023	EX-99.1	Integra LifeSciences Reports Third Quarter 2023 Financial Results News Release Integra LifeSciences Reports Third Quarter 2023 Financial Results PRINCETON, N.
October 25, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
October 25, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpora
August 16, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporat
July 27, 2023	EX-99.1	Integra LifeSciences Reports Second Quarter 2023 Financial Results News Release Integra LifeSciences Reports Second Quarter 2023 Financial Results PRINCETON, N.
July 27, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
July 27, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporatio
June 21, 2023	EX-99.1	Exhibit 99.1 Integra LifeSciences Appoints Lea Daniels Knight, Executive Vice President and Chief Financial Officer Princeton, New Jersey, June 21, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the a knightpressrelease Exhibit 99.1 Integra LifeSciences Appoints Lea Daniels Knight, Executive Vice President and Chief Financial Officer Princeton, New Jersey, June 21, 2023 (GLOBE NEWSWIRE) - Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Lea Daniels Knight as executive vice president and chief financial officer, effective June 28, 2023. Ms. Knight has ov
June 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 INTEGRA LIFESCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporatio
May 31, 2023	SD	United States Securities and Exchange Commission Washington, D.C. 20549 FORM SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) United States Securities and Exchange Commission Washington, D.C. 20549 FORM SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation or organization) Commission File Number (I.R.S. Employer Identification No.) 1100 CAMPUS ROAD PRINCETON, NEW JERSEY 085
May 31, 2023	EX-1.01	Conflict Minerals Report EX-1.01 2 formsd-xexhibit101.htm EX-1.01 Exhibit 1.01 Conflict Minerals Report of Integra LifeSciences Holdings Corporation Filed on May 31, 2023 As required by Items 1.01 and 1.02 of Form SD This report for the year ended December 31, 2022 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule imposes certain reporting obligations on re
May 23, 2023	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporation
May 16, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporation
April 26, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
April 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 INTEGRA LIFESCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporati
April 26, 2023	EX-10.4	Amendment No. 4 to Receivables Financing Agreement and Reaffirmation of Performance Guaranty, dated as of April 17, 2023, by and among, Integra Receivables LLC, Integra LifeSciences Sales LLC, as Servicer, PNC Bank, National Associations, as Administrative Agent, PNC Capital Markets LLC, as Structuring Agent, Committed Lender and Group Agent, and certain lenders and group agents that are parties thereto from time to time (Incorporated by reference to Exhibit 10.4 to the Company Quarterly Report on Form 10-Q for the quarter ended March 31, 2023) Exhibit 10.4 AMENDMENT NO. 4 TO RECEIVABLES FINANCING AGREEMENT AND REAFFIRMATION OF PERFORMANCE GUARANTY This AMENDMENT NO. 4 TO RECEIVABLES FINANCING AGREEMENT AND REAFFIRMATION OF PERFORMANCE GUARANTY (this “Amendment”), dated as of April 17, 2023 is entered into by and among INTEGRA RECEIVABLES LLC (“Integra”), as borrower under the Receivables Financing Agreement (as defined below) (in such c
April 26, 2023	EX-99.1	Integra LifeSciences Reports First Quarter 2023 Financial Results News Release Integra LifeSciences Reports First Quarter 2023 Financial Results PRINCETON, N.
April 6, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
March 24, 2023	EX-10.2	Ratification Agreement, dated as of March 24, 2023, between Integra LifeSciences Holdings Corporation, the Subsidiary Guarantors of Integra LifeSciences Holdings Corporation and Bank of America, N.A., as Administrative Agent (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on March 24, 2023) integraratificationagree Exhibit 10.2 RATIFICATION AGREEMENT RATIFICATION AGREEMENT dated as of March 24, 2023 (as amended, supplemented or oth- erwise modified from time to time, this “Ratification Agreement”), among Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Borrower”), the subsidiaries identified on the signature pages hereto (together with the Borrower, the “Reaffi
March 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 INTEGRA LIFESCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorporati
March 24, 2023	EX-10.1	Seventh Amended and Restated Credit Agreement, dated as of March 24, 2023, among Integra LifeSciences Holdings Corporation, the lenders party thereto, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Citibank N.A., JPMorgan Chase Bank, N.A., Morgan Stanley MUFG Loan Partners, LLC, PNC Bank, N.A., Truist Securities, Inc. and Wells Fargo Bank, N.A., as Co-Syndication Agents, and The Bank of Nova Scotia, BMO Harris Bank N.A., BNP Paribas, Capital One, National Association, Citizens Bank, N.A., DNB Bank ASA, New York Branch, Santander Bank, N.A. and TD Bank, N.A., as Co-Documentation (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 24, 2023) integra-7tharcreditagree Exhibit 10.1 Execution Version Published CUSIP Number: 45810CAT5 SEVENTH AMENDED AND RESTATED CREDIT AGREEMENT Dated as of March 24, 2023 among INTEGRA LIFESCIENCES HOLDINGS CORPORATION, a Delaware corporation, as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent and as the Swing Line Lender and an L/C Issuer, CITIBANK N.A., JPMORGAN CHASE BANK, N.A., MORGAN STA
February 22, 2023	EX-10.3(K)	Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Non-Qualified Stock Option Award Agreement (Incorporated by reference to Exhibit 10.3(k) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022) Exhibit 10.3(k) INTEGRA LIFESCIENCES HOLDINGS CORPORATION 2003 EQUITY INCENTIVE PLAN NON-QUALIFIED STOCK OPTION AGREEMENT NON-QUALIFIED STOCK OPTION AGREEMENT (together with the attached Notice of Grant of Stock Options and Option Agreement (“Notice of Grant”), the “Option Agreement”) made as of the date (the “Grant Date”) set forth in Notice of Grant, between Integra LifeSciences Holdings Corpora
February 22, 2023	EX-99.1	INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Exhibit 99.1 News Release Integra LifeSciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance Princeton, New Jersey, February 22, 2023 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2022, consistent with its preliminary financial results announced o
February 22, 2023	EX-3.3	Third Amended and Restated Bylaws of Integra LifeSciences Holdings Corporation, effective as of February 21, 2023 (Incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed on February 22, 2023) Exhibit 3.3 Effective as of February 21, 2023 THIRD AMENDED AND RESTATED BYLAWS OF INTEGRA LIFESCIENCES HOLDINGS CORPORATION (the “Corporation”) ARTICLE 1 OFFICES Section 1.01 Offices. The Corporation may have offices at such places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the Corporation may require. ARTICLE 2 MEETI
February 22, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Integra LifeSciences Holdings Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Type Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Stock, par value $0.
February 22, 2023	S-3ASR	As filed with the Securities and Exchange Commission on February 22, 2023 Table of Contents As filed with the Securities and Exchange Commission on February 22, 2023 Registration No.
February 22, 2023	EX-10.3(L)	Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Restricted Stock Award Agreement – OUS (Incorporated by reference to Exhibit 10.3(l) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 Exhibit 10.3(l) RESTRICTED STOCK UNIT AWARD AGREEMENT FOR PARTICIPANTS OUTSIDE THE UNITED STATES THIS RESTRICTED STOCK UNIT AWARD AGREEMENT including any exhibit, appendix or addendum hereto (the “Award Agreement”), dated as of [ ] (the “Award Date”), is made by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and [ ] hereinafter referred to as the “Pa
February 22, 2023	EX-10.3(J)	Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Performance Stock Unit Award Agreement (Incorporated by reference to Exhibit 10.3(j) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022) Exhibit 10.3(j) PERFORMANCE STOCK AGREEMENT THIS PERFORMANCE STOCK AGREEMENT (the “Award Agreement”), dated as of [ ] (the “Award Date”), is made by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and [ ], an employee of the Company (or one or more of its Related Corporations or Affiliates), hereinafter referred to as the “Participant.” WHEREAS, the C
February 22, 2023	EX-10.3(I)	Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Restricted Stock Agreement – Executive Officers (Incorporated by reference to Exhibit 10.3(i) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022) Exhibit 10.3(i) RESTRICTED STOCK AGREEMENT THIS RESTRICTED STOCK AGREEMENT (the “Award Agreement”), dated as of [ ] (the “Award Date”), is made by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and [ ], an employee of the Company (or one or more of its Related Corporations or Affiliates), hereinafter referred to as the “Participant”: WHEREAS, the Com
February 22, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
February 22, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
February 22, 2023	EX-4.4	Description of Securities+ Exhibit 4.4 Description of the Company’s Common Stock Registered Under Section 12 of the Exchange Act The following is a description of the common stock of Integra LifeSciences Holdings Corporation (the “Company”). The description does not purport to be complete and is subject to and qualified in its entirety by reference to the Company’s amended and restated certificate of incorporation, or the c
February 22, 2023	EX-21.1	Subsidiaries of the Company+ EXHIBIT 21.1 Subsidiaries of Integra LifeSciences Holdings Corporation Name of Subsidiary State or Country of Incorporation or Organization ACell, Inc. Delaware Arkis Biosciences Inc. Delaware Ascension Orthopedics Limited United Kingdom BIMECO, Inc. Florida BioD, LLC Delaware BioDlogics, LLC Delaware BioRecovery, LLC Delaware CardioDyne, Inc. Massachusetts Cathtec Incorporated Massachusetts Cavea
February 22, 2023	EX-10.3(H)	Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Restricted Stock Award Agreement – Directors (Incorporated by reference to Exhibit 10.3(h) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022) Exhibit 10.3(h) RESTRICTED STOCK AGREEMENT THIS RESTRICTED STOCK AGREEMENT (the “Award Agreement”), dated as of [ ] (the “Award Date”), is made by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and [ ], a non-employee director of the Company, hereinafter referred to as the “Participant”: WHEREAS, the Company maintains the Integra LifeSciences Holding
February 14, 2023	EX-99.B	Joint Filing Agreement EX-99.B 3 d430695dex99b.htm EX-99.B Page 9 of 9 EXHIBIT B Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G/A (including amendments thereto) with respect to the common stock, par value $.01 per share of Integra LifeSciences Holdings
February 14, 2023	SC 13G/A	IART / Integra Lifesciences Holdings Corp / Tru St Partnership, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d430695dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 20)* Integra LifeSciences Holdings Corporation (Name of Issuer) Common stock, $.01 par value (Title of Class of Securities) 457985208 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the
February 14, 2023	EX-99.A	Group Members Tru St Partnership LP Provco, LLC EX-99.A 2 d430695dex99a.htm EX-99.A Page 8 of 9 EXHIBIT A Group Members Tru St Partnership LP Provco, LLC
February 9, 2023	SC 13G/A	IART / Integra Lifesciences Holdings Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Integra LifeSciences Holdings Corp. Title of Class of Securities: Common Stock CUSIP Number: 457985208 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Sche
February 6, 2023	SC 13G/A	IART / Integra Lifesciences Holdings Corp / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check
January 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2023 INTEGRA LIFESCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction Of Incorporation) (Commission File Number) (IRS Employer Identification No.
January 25, 2023	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpora
January 25, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpora
January 10, 2023	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpora
January 10, 2023	EX-99.1	Exhibit 99.1 Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials Fourth Quarter 2022  Fourth quarter 2022 revenue is expected to be in a range of $397 million to $398 million, representing a decrease of appro Exhibit 99.1 Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials Fourth Quarter 2022  Fourth quarter 2022 revenue is expected to be in a range of $397 million to $398 million, representing a decrease of approximately 2% on a reported basis and an increase of approximately 3% on an organic basis compared to 2021.  Fourth quarter 2022 adjusted earnings per
January 10, 2023	EX-99.2	2023 JP Morgan Healthcare Conference January 11, 2023 Exhibit 99.2 Safe Harbor Disclosure 2 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risk 2023 JP Morgan Healthcare Conference January 11, 2023 Exhibit 99.2 Safe Harbor Disclosure 2 Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact,
December 14, 2022	EX-10.1	Change in Control Severance Program - 1 - SC1:4719683.2 Exhibit 10.1 INTEGRA LIFESCIENCES HOLDINGS CORPORATION CHANGE IN CONTROL SEVERANCE PROGRAM This Change in Control Severance Program (this ?Program?) is effective as of January 1, 2023 (the ?Effective Date?). This Program is designed to provide selected officers and key employees of Integra LifeSciences Holdings Corporation (the ?Company?) with certain benefits upon a Qualifying
December 14, 2022	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
December 1, 2022	EX-99.2	Integra LifeSciences Announces Definitive Agreement to Acquire Surgical Innovation Associates (SIA) and Plans for $150 Million Share Repurchase Acquisition will add distinct new product solution for plastic and reconstructive surgery to address clini Integra LifeSciences Announces Definitive Agreement to Acquire Surgical Innovation Associates (SIA) and Plans for $150 Million Share Repurchase Acquisition will add distinct new product solution for plastic and reconstructive surgery to address clinical needs and improve patient outcomes Deploys capital to support strong profitable growth and greater returns for our shareholders PRINCETON, N.
December 1, 2022	EX-99.1	ACQUISTION OF SURGICAL INNOVATION ASSOCIATES (SIA), INC. DECEMBER 01, 2022 Confidential ‐ For internal use only Legal Information 2 Forward‐Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Sec ACQUISTION OF SURGICAL INNOVATION ASSOCIATES (SIA), INC. DECEMBER 01, 2022 Confidential ? For internal use only Legal Information 2 Forward?Looking Statements This presentation contains forward?looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All stat
December 1, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpor
October 26, 2022	EX-10.3	Form of Non-Deferred Contract Stock/Restricted Units Award Agreement (Executive Officers) Exhibit 10.3 Notice of Grant of Award and Award Agreement Integra LifeSciences Holdings Corporation ID: 51-0317849 1100 Campus Road Princeton, New Jersey 08540 [Name] [Address] Award Number: [Award#] Plan: [Plan#] ID: [EMP ID] Effective [Grant Date], you have been granted [Total Shares] Restricted Stock Units (RSUs) based on a closing price of US$[IART Close Price]. These units are restricted unti
October 26, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
October 26, 2022	EX-99.1	Integra LifeSciences Reports Third Quarter 2022 Financial Results News Release Integra LifeSciences Reports Third Quarter 2022 Financial Results PRINCETON, N.
October 26, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction of Incorpora
October 11, 2022	SC 13G/A	IART / Integra Lifesciences Holdings Corp / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) September 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu
September 23, 2022	EX-10.1	Separation Agreement and General Release, dated September 23, 2022, by and between Glenn Coleman, Integra LifeSciences Corporation and Integra LifeSciences Holdings Corporation (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 23, 2022) Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (?Agreement?) is made and entered into by and between Glenn Coleman (?Employee?), Integra LifeSciences Corporation (?the Company?) and Integra LifeSciences Holdings Corporation (?Parent?): WHEREAS, Parent and Company are eliminating the position of Chief Operating Officer; WHEREAS, the Employee will
September 23, 2022	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpo
August 29, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 25, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction Of Incorporation) (Commission File Number) (IRS Employer Identification No.
August 24, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 18, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 0-26224 51-0317849 (State or Other Jurisdiction Of Incorporation) (Commission File Number) (IRS Employer Identification No.
July 27, 2022	S-8	As filed with the Securities and Exchange Commission on July 27, 2022 As filed with the Securities and Exchange Commission on July 27, 2022 Registration No.
July 27, 2022	EX-FILING FEES	Calculation of Filing Fee Table+ Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Integra LifeSciences Holdings Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Newly Registered Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Proposed Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Fees to be Paid Other Deferred Compensation Obligations Rule 457(h) $5,000,000.
July 27, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
July 27, 2022	EX-24.1	Powers of Attorney+ EX-24.1 4 d316421dex241.htm EX-24.1 Exhibit 24.1 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below, hereby constitutes and appoints Jan De Witte, Carrie L. Anderson, and Eric I. Schwartz and each acting alone, his or her true and lawful attorneys-in-fact and agents, with full power of resubstitution and substitution, for him or her and in his or her n
July 27, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporatio
July 27, 2022	EX-99.1	Integra LifeSciences Reports Second Quarter 2022 Financial Results News Release Integra LifeSciences Reports Second Quarter 2022 Financial Results PRINCETON, N.
July 19, 2022	EX-99.1	Integra LifeSciences Appoints Renee Lo as Director Integra LifeSciences Appoints Renee Lo as Director Princeton, New Jersey, July 19, 2022 (GLOBE NEWSWIRE) - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Renee Lo to its board of directors as an independent director to fill an existing vacancy, effective July 18, 2022.
July 19, 2022	EX-10.1	Form of Indemnification Agreement, by and between Integra LifeSciences Holdings Corporation and each of its directors and executive officers (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 19, 2022) Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of , by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the ?Company?), and (?Indemnitee?). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, directors,
July 19, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporatio
July 8, 2022	SC 13G/A	IART / Integra Lifesciences Holdings Corp / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Integra LifeSciences Holdings Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) June 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
May 31, 2022	SD	United States Securities and Exchange Commission Washington, D.C. 20549 Form SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other United States Securities and Exchange Commission Washington, D.C. 20549 Form SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation or organization) Commission File Number (I.R.S. Employer Identification No.) 1100 CAMPUS ROAD PRINCETON, NEW JERSEY 085
May 31, 2022	EX-1.01	Conflict Minerals Report Exhibit 1.01 CONFLICT MINERALS REPORT Conflict Minerals Report of Integra LifeSciences Holdings Corporation Filed on May 31, 2022 As required by Items 1.01 and 1.02 of Form SD This report for the year ended December 31, 2021 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the ?Rule?). The Rule was adopted by the Securities and Exchange Commission (the
May 17, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation
April 27, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
April 27, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporati
April 27, 2022	EX-99.1	Integra LifeSciences Reports First Quarter 2022 Financial Results News Release Integra LifeSciences Reports First Quarter 2022 Financial Results PRINCETON, N.
April 8, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14
February 24, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
February 24, 2022	EX-21.1	Subsidiaries of the Company+ EXHIBIT 21.1 Subsidiaries of Integra LifeSciences Holdings Corporation Name of Subsidiary State or Country of Incorporation or Organization ACell, Inc. Delaware Arkis Biosciences Inc. Delaware Ascension Orthopedics Limited United Kingdom BIMECO, Inc. Florida BioD, LLC Delaware BioDlogics, LLC Delaware BioRecovery, LLC Delaware CardioDyne, Inc. Massachusetts Cathtec Incorporated Massachusetts Cavea
February 24, 2022	EX-4.4	Description of Securities+ Exhibit 4.4 Description of the Company?s Common Stock Registered Under Section 12 of the Exchange Act The following is a description of the common stock of Integra LifeSciences Holdings Corporation (the ?Company?). The description does not purport to be complete and is subject to and qualified in its entirety by reference to the Company?s amended and restated certificate of incorporation and its a
February 23, 2022	EX-99.1	INTEGRA LIFESCIENCES HOLDINGS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS News Release Integra LifeSciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides 2022 Financial Guidance Princeton, New Jersey, February 23, 2022 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2021, consistent with its preliminary revenue results announced on January 11, 2022.
February 23, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpor
February 14, 2022	EX-99.(A)	Group Members Tru St Partnership LP Provco Leasing Corporation EX-99.(A) 2 d303422dex99a.htm EX-99.(A) Page 8 of 9 EXHIBIT A Group Members Tru St Partnership LP Provco Leasing Corporation
February 14, 2022	SC 13G/A	IART / Integra Lifesciences Holdings Corp / Tru St Partnership, L.P. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 19)* Integra LifeSciences Holdings Corporation (Name of Issuer) Common stock, $.01 par value (Title of Class of Securities) 457985208 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p
February 14, 2022	EX-99.(B)	Joint Filing Agreement EX-99.(B) 3 d303422dex99b.htm EX-99.(B) Page 9 of 9 EXHIBIT B Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G/A (including amendments thereto) with respect to the common stock, par value $.01 per share of Integra LifeSciences Hold
February 11, 2022	SC 13G/A	IART / Integra Lifesciences Holdings Corp / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Integra LifeSciences Holdings Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 10, 2022	SC 13G/A	IART / Integra Lifesciences Holdings Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Integra LifeSciences Holdings Corp. Title of Class of Securities: Common Stock CUSIP Number: 457985208 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Sche
February 4, 2022	SC 13G/A	IART / Integra Lifesciences Holdings Corp / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
January 13, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpora
January 11, 2022	EX-99.1	Integra LifeSciences Reports Preliminary Fourth Quarter and Full-Year 2021 Revenue and Plans $125 Million Share Repurchase Integra LifeSciences Reports Preliminary Fourth Quarter and Full-Year 2021 Revenue and Plans $125 Million Share Repurchase ?Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year.
January 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpora
December 17, 2021	EX-24.1	Powers of Attorney.+ EX-24.1 4 d260411dex241.htm EX-24.1 Exhibit 24.1 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jan D. De Witte, Carrie L. Anderson, and Eric I. Schwartz, or any one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name,
December 17, 2021	S-8	As filed with the Securities and Exchange Commission on December 17, 2021. As filed with the Securities and Exchange Commission on December 17, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Integra LifeSciences Holdings Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 51-0317849 (State or Other Jurisdiction of Incorporation or Or
December 15, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpora
December 15, 2021	EX-10.1	Change in Control Severance Program Exhibit 10.1 INTEGRA LIFESCIENCES HOLDINGS CORPORATION CHANGE IN CONTROL SEVERANCE PROGRAM This Change in Control Severance Program (this ?Program?) is effective as of January 1, 2022 (the ?Effective Date?). This Program is designed to provide selected officers and key employees of Integra LifeSciences Holdings Corporation (the ?Company?) with certain benefits upon a Qualifying Termination in conn
December 1, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpora
November 2, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpora
November 2, 2021	EX-99.1	Integra LifeSciences Reports Third Quarter 2021 Financial Results News Release Integra LifeSciences Reports Third Quarter 2021 Financial Results Third Quarter 2021 Highlights ?Revenues of $386.
November 2, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
October 28, 2021	EX-99.1	Integra LifeSciences Announces Jan De Witte as President and Chief Executive Officer 30-year healthcare and technology veteran with extensive global executive experience and diverse expertise in R&D, commercialization, product management, digital inn Integra LifeSciences Announces Jan De Witte as President and Chief Executive Officer 30-year healthcare and technology veteran with extensive global executive experience and diverse expertise in R&D, commercialization, product management, digital innovation and operations PRINCETON, New Jersey, October 28, 2021 - Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that it has appointed Jan D.
October 28, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpora
October 28, 2021	EX-10.1	Employment Agreement, dated October 28, 2021, by and between Integra LifeSciences Holdings Corporation, Integra LifeSciences Corporation and Jan De Witte (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 28, 2021) EX-10.1 2 ex101xintegraemployment.htm EX-10.1 1 US-DOCS\126937663.3 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), by and between Integra LifeSciences Holdings Corporation, a Delaware Corporation (“Holdings”) and Integra LifeSciences Corporation (“OpCo” and, together with Holdings, the “Company”), and Jan De Witte (“Executive”) is entered into as of October 28, 2021 and shall b
July 29, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
July 29, 2021	EX-10.1	Amendment No. 1 to Receivables Financing Agreement and Reaffirmation of Performance Guaranty, dated as of March 29, 2019, by and among Integra Receivables LLC, Integra LifeSciences Sales LLC, as Servicer, PNC Bank, National Associations, as Administrative Agent, Committed Lender and Group Agent, Mizuho Bank, Ltd., as Committed Lender and Group Agent and PNC Capital Markets LLC, as Structuring Agent, and certain lenders and group agents that are parties thereto from time to time (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021) Exhibit 10.1 AMENDMENT NO. 3 TO RECEIVABLES FINANCING AGREEMENT AND REAFFIRMATION OF PERFORMANCE GUARANTY This AMENDMENT NO. 3 TO RECEIVABLES FINANCING AGREEMENT AND REAFFIRMATION OF PERFORMANCE GUARANTY (this ?Amendment?), dated as of May 28, 2021 is entered into by and among INTEGRA RECEIVABLES LLC (?Integra?), as borrower under the Receivables Financing Agreement (as defined below) (in such cap
July 28, 2021	EX-99.1	Integra LifeSciences Reports Second Quarter 2021 Financial Results Raises Full-Year 2021 Guidance News Release Integra LifeSciences Reports Second Quarter 2021 Financial Results Raises Full-Year 2021 Guidance Second Quarter 2021 Highlights ?Revenues of $390.
July 28, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporatio
June 24, 2021	EX-99.1	Integra LifeSciences Announces CEO Succession Plan Peter Arduini to serve as President and CEO through the end of 2021 Candidate search launched to identify successor Integra LifeSciences Announces CEO Succession Plan Peter Arduini to serve as President and CEO through the end of 2021 Candidate search launched to identify successor PRINCETON, New Jersey, June 24, 2021 - Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that Peter Arduini will step down as Chief Executive Officer at the end of 2021 to accept the role of President and Chief Executive Officer of GE Healthcare.
June 24, 2021	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as Specified in its Charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporatio
May 28, 2021	SD	United States Securities and Exchange Commission Washington, D.C. 20549 Form SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other United States Securities and Exchange Commission Washington, D.C. 20549 Form SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation or organization) Commission File Number (I.R.S. Employer Identification No.) 1100 CAMPUS ROAD PRINCETON, NEW JERSEY 085
May 28, 2021	EX-1.01	Conflict Minerals Report Exhibits Exhibit 1.01 CONFLICT MINERALS REPORT Conflict Minerals Report of Integra LifeSciences Holdings Corporation Filed on May 28, 2021 As required by Items 1.01 and 1.02 of Form SD This report for the year ended December 31, 2020 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the ?Rule?). The Rule was adopted by the Securities and Exchange Commission (the ?SE
May 20, 2021	EX-99.1	Integra LifeSciences Hosts Virtual Investor Day Integra LifeSciences Hosts Virtual Investor Day PRINCETON, New Jersey, May 20, 2021 - Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will host an Investor Day meeting from 8:30 a.
May 20, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation
May 18, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation
May 18, 2021	EX-10.1	Amendment No. 1 to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 13, 2024) EXHIBIT 10.1 INTEGRA LIFESCIENCES HOLDINGS CORPORATION FIFTH AMENDED AND RESTATED 2003 EQUITY INCENTIVE PLAN (EFFECTIVE AS OF May 14, 2021) WHEREAS, Integra LifeSciences Holdings Corporation (the ?Company?) desires to have the ability to award certain equity-based benefits to certain ?Key Employees? and ?Associates? (as defined below); NOW, THEREFORE, the Integra LifeSciences Holdings Corporation
April 29, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
April 28, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporati
April 28, 2021	EX-99.1	Integra LifeSciences Reports First Quarter 2021 Financial Results EX-99.1 2 ex991-q12021earningsrelea.htm EX-99.1 News Release Investor Relations Contacts: Michael Beaulieu Director, Investor Relations (609) 529-4812 [email protected] Media Contact: Laurene Isip Vice President, Global Corporate Communications and Public Relations (609) 208-8121 [email protected] Integra LifeSciences Reports First Quarter 2021 Financial Results Princeton
April 9, 2021	DEF 14A	Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 1, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporatio
April 1, 2021	EX-99.1	Integra LifeSciences Appoints Shaundra Clay as Director EX-99.1 2 pressreleaseapril12021.htm EX-99.1 Integra LifeSciences Appoints Shaundra Clay as Director Princeton, New Jersey, April 1, 2021 (GLOBE NEWSWIRE) - Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the appointment of Shaundra Clay to its board of directors, effective today. “We are delighted to welcome Shaundra, a seasone
February 23, 2021	EX-4.13	Description of Securities+ Exhibit 4.13 Description of the Company?s Common Stock Registered Under Section 12 of the Exchange Act The following is a description of the common stock of Integra LifeSciences Holdings Corporation (the ?Company?). The description does not purport to be complete and is subject to and qualified in its entirety by reference to the Company?s amended and restated certificate of incorporation and its
February 23, 2021	EX-21	Subsidiaries of the Company+ EXHIBIT 21 Subsidiaries of Integra LifeSciences Holdings Corporation Name of Subsidiary State or Country of Incorporation or Organization Arkis Biosciences Inc.
February 23, 2021	EX-2.1B	Agreement and Plan of Merger by among Integra LifeSciences Holdings Corporation and ACell Inc. dated as of December 15, 2020 (Incorporated by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020) EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among Integra LifeSciences Holdings Corporation; ILS OCEAN 12-20 CORP.
February 23, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
February 18, 2021	EX-99.1	Integra LifeSciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides 2021 Financial Guidance News Release Contact: Investor Relations: Michael Beaulieu Director, Investor Relations (609) 750-2827 michael.
February 18, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpor
February 16, 2021	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Integra LifeSciences Holdings Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 16, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 18)* Integra LifeSciences Holdings Corporation (Name of Issuer) Common stock, $.01 par value (Title of Class of Securities SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 18)* Integra LifeSciences Holdings Corporation (Name of Issuer) Common stock, $.01 par value (Title of Class of Securities) 457985208 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p
February 12, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpor
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Integra LifeSciences Holdings Corp. Title of Class of Securities: Common Stock CUSIP Number: 457985208 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Sche
February 4, 2021	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
January 20, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpora
January 20, 2021	EX-99.1	Integra LifeSciences Completes the Acquisition of ACell, Inc. Integra LifeSciences Completes the Acquisition of ACell, Inc. PRINCETON, New Jersey, January 20, 2021 - Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-disclosed acquisition of ACell, Inc. “Acquiring ACell and its proprietary MatriStem UBM™ technologies will enable Integra to provide more comprehensiv
January 14, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpora
January 14, 2021	EX-99.1	Integra LifeSciences Announces Preliminary Fourth Quarter and Full-Year 2020 Revenue Results; Will Host Fourth Quarter Financial Results Conference Call on February 18, 2021 Integra LifeSciences Announces Preliminary Fourth Quarter and Full-Year 2020 Revenue Results; Will Host Fourth Quarter Financial Results Conference Call on February 18, 2021 PRINCETON, New Jersey, January 14, 2021 - Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2020 revenue results.
January 4, 2021	EX-99.1	Integra LifeSciences Completes the Sale of its Extremity Orthopedics Business to Smith+Nephew Integra LifeSciences Completes the Sale of its Extremity Orthopedics Business to Smith+Nephew PRINCETON, New Jersey, January 4, 2021 - Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has completed its previously announced divestiture of its Extremity Orthopedics business to Smith+Nephew (LSE:SN, NYSE:SNN).
January 4, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2021 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporat
December 16, 2020	EX-99.1	Integra LifeSciences Announces Definitive Agreement to Acquire ACell, Inc. Adds proprietary technology platform and complementary products to grow Integra’s regenerative portfolio Integra LifeSciences Announces Definitive Agreement to Acquire ACell, Inc. Adds proprietary technology platform and complementary products to grow Integra’s regenerative portfolio PRINCETON, New Jersey, December 16, 2020 - Integra LifeSciences Holdings Corporation (NASDAQ:IART) a leading global medical technology company, today announced it has entered into a definitive agreement to acquire ACell,
December 16, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpor
December 10, 2020	EX-4.1	First Supplemental Indenture, by and between Integra LifeSciences Holdings Corporation and Citibank, N.A., as trustee (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on December 9, 2020) INTEGRA LIFESCIENCES HOLDINGS CORPORATION and CITIBANK, N.A., as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 9, 2020 FIRST SUPPLEMENTAL INDENTURE dated as of December 9, 2020 (this “First Supplemental Indenture”), between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and Citibank, N.A., a national association, as trustee (the “Trustee”). Capitaliz
December 10, 2020	EX-10.1	Change in Control Severance Program. EXHIBIT A INTEGRA LIFESCIENCES HOLDINGS CORPORATION CHANGE IN CONTROL SEVERANCE PROGRAM This Change in Control Severance Program (this “Program”) is effective as of January 1, 2021 (the “Effective Date”).
December 10, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpora
December 10, 2020	SC 13G/A	IART / Integra LifeSciences Holdings Corp. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) November 30, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
October 29, 2020	EX-2.1	Put Option Agreement, dated September 29, 2020, between the Company and certain of its subsidiaries and Smith & Nephew USD Limited, a subsidiary of Smith+Nephew (including the Purchase and Sale Agreement attached as Appendix 1 thereto) Execution Version To: The Sellers (as defined in the PSA) PRIVATE AND CONFIDENTIAL Date: September 29, 2020 Dear Sirs, Project Artemis We refer to our recent discussions relating to the contemplated acquisition by the Buyer or its applicable Buyer Designee(s) of the Ascension Shares, the ISC Shares and the Purchased Assets (the Proposed Transaction).
October 29, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
October 28, 2020	EX-99.1	Integra LifeSciences Reports Third Quarter 2020 Financial Results EX-99.1 2 ex991-q32020earningsre.htm EXHIBIT 99.1 News Release Investor Relations Contacts: Michael Beaulieu Director, Investor Relations (609) 529-4812 [email protected] Media Contact: Laurene Isip Senior Director, Global Corporate Communications (609) 750-7984 [email protected] Integra LifeSciences Reports Third Quarter 2020 Financial Results Princeton, New Jersey, Octo
October 28, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpora
October 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporat
October 6, 2020	EX-99.1	Integra LifeSciences Announces Preliminary Third Quarter Revenue Results; Will Host Third Quarter 2020 Financial Results Conference Call on October 28, 2020 Integra LifeSciences Announces Preliminary Third Quarter Revenue Results; Will Host Third Quarter 2020 Financial Results Conference Call on October 28, 2020 PRINCETON, New Jersey, October 6, 2020 - Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary third quarter financial results.
September 29, 2020	EX-99.1	Integra LifeSciences Announces Definitive Agreement to Divest its Extremity Orthopedics Business to Smith+Nephew for $240 Million Integra LifeSciences Announces Definitive Agreement to Divest its Extremity Orthopedics Business to Smith+Nephew for $240 Million PRINCETON, New Jersey, September 29, 2020 - Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has entered into a definitive agreement to sell its Extremity Orthopedics business to Smith+Nephew (LSE:SN, NYSE:SNN) for $240 million in cash.
September 29, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorpo
August 10, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
August 10, 2020	EX-10.1	Amendment to the Integra LifeSciences Holdings Corporation Fourth Amended and Restated 2003 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020) AMENDMENT TO THE INTEGRA LIFESCIENCES HOLDINGS CORPORATION FOURTH AMENDED AND RESTATED 2003 EQUITY INCENTIVE PLAN (EFFECTIVE AS OF July 16, 2020) THIS AMENDMENT (this “Amendment”) to the Integra Lifesciences Holdings Corporation Fourth Amended and Restated 2003 Equity Incentive Plan (the “Plan”) is made by Integra Lifesciences Holdings Corporation (the “Company”) as of the date set forth at the end of this Amendment.
August 10, 2020	EX-99.1	Integra LifeSciences Reports Second Quarter 2020 Financial Results News Release Investor Relations Contacts: Michael Beaulieu Director, Investor Relations (609) 529-4812 michael.
August 10, 2020	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporat
August 10, 2020	EX-10.2	Amendment to the Third Amended and Restated Employment Agreement between the Company and Peter J. Arduini August 7, 2020 Re: Amendment to Employment Agreement Dear Peter: This letter (this “Amendment”) amends that certain Third Amended and Restated Employment Agreement by and between you and Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), dated October 24, 2017 (the “Employment Agreement”), as follows.
August 3, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporatio
July 20, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporatio
July 20, 2020	EX-4.1	Amendment, dated July 14, 2020, to that Sixth Amended and Restated Credit Agreement, among Integra LifeSciences Holdings Corporation, a syndicate of lending banks, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Citibank N.A., Morgan Stanley MUFG Loan Partners, LLC and Wells Fargo Bank, N.A. as Co-Syndication Agents, and PNC Bank, N.A., Bank of Nova Scotia, Bank of the West, BBVA USA, Capital One, National Association, Citizens Bank, N.A., DNB Capital LLC, Santander Bank, N.A., T.D. Bank, N.A. and Truist Bank, as Co-Documentation Agents (as amended, restated, modified and supplemented from time to time prior to the date hereof, the “Credit Agreement”) (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on July 20, 2020). Execution Version AMENDMENT NO. 1, dated as of July 14, 2020 (this “Amendment”) to the Sixth Amended and Restated Credit Agreement, dated as of February 3, 2020 (as amended, restated, modified and supplemented from time to time prior to the date hereof, the “Existing Credit Agreement”) by and among INTEGRA LIFESCIENCES HOLDINGS CORPORATION, a Delaware corporation (the “Borrower”), the subsidiaries
July 9, 2020	EX-99.1	Integra LifeSciences Announces Preliminary Second Quarter Revenue Results; Will Host Second Quarter 2020 Financial Results Conference Call on August 10, 2020 Integra LifeSciences Announces Preliminary Second Quarter Revenue Results; Will Host Second Quarter 2020 Financial Results Conference Call on August 10, 2020 PRINCETON, New Jersey, July 9, 2020 - Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary second quarter financial results.
July 9, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation
May 29, 2020	EX-1.01	Conflict Minerals Report EX-1.01 Exhibits Exhibit 1.01 CONFLICT MINERALS REPORT Conflict Minerals Report of Integra LifeSciences Holdings Corporation Filed on May 29, 2020 As required by Items 1.01 and 1.02 of Form SD This report for the year ended December 31, 2019 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commission
May 29, 2020	SD	- FORM SD Form SD United States Securities and Exchange Commission Washington, D.C. 20549 Form SD Specialized Disclosure Report INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation or organization) Commission File Number (I.R.S. Employer Identification No.) 1100 CAMPUS ROAD PRINCETON, NEW JE
May 21, 2020	EX-99.1	Integra LifeSciences Announces Key Executive Leadership Changes Integra LifeSciences Announces Key Executive Leadership Changes Princeton, New Jersey, May 21, 2020 (GLOBE NEWSWIRE) - Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced changes to its executive leadership team.
May 21, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation
May 18, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation
May 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporation
May 7, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.
May 7, 2020	EX-99.1	Integra LifeSciences Reports First Quarter 2020 Financial Results News Release Investor Relations Contacts: Michael Beaulieu Director, Investor Relations (609) 750-2827 michael.
April 23, 2020	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 21, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporati
April 8, 2020	DEF 14A	IART / Integra LifeSciences Holdings Corp. DEF 14A - - DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incorporatio
April 7, 2020	EX-99.1	Integra LifeSciences Announces Preliminary First Quarter Revenue Results and Provides an Update on COVID-19 Impact; Will Host First Quarter 2020 Financial Results Conference Call on May 7, 2020 Integra LifeSciences Announces Preliminary First Quarter Revenue Results and Provides an Update on COVID-19 Impact; Will Host First Quarter 2020 Financial Results Conference Call on May 7, 2020 PRINCETON, New Jersey, April 7, 2020 - Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary first quarter financial results.
February 21, 2020	EX-21	Subsidiaries of the Company+ EXHIBIT 21 Subsidiaries of Integra LifeSciences Holdings Corporation Name of Subsidiary State or Country of Incorporation or Organization Arkis Biosciences Inc.

IART / Integra LifeSciences Holdings Corporation - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)

Other Listings